Literature DB >> 29339504

Complement pathway gene activation and rising circulating immune complexes characterize early disease in HIV-associated tuberculosis.

Hanif Esmail1,2,3,4, Rachel P Lai5, Maia Lesosky2,3,6, Katalin A Wilkinson2,3,5, Christine M Graham7, Stuart Horswell5, Anna K Coussens2,3,8, Clifton E Barry2,3,9,10,11, Anne O'Garra7,12, Robert J Wilkinson1,2,3,5.   

Abstract

The transition between latent and active tuberculosis (TB) occurs before symptom onset. Better understanding of the early events in subclinical disease will facilitate the development of diagnostics and interventions that improve TB control. This is particularly relevant in the context of HIV-1 coinfection where progression of TB is more likely. In a recent study using [18F]-fluoro-2-deoxy-d-glucose positron emission/computed tomography (FDG-PET/CT) on 35 asymptomatic, HIV-1-infected adults, we identified 10 participants with radiographic evidence of subclinical disease, significantly more likely to progress than the 25 participants without. To gain insight into the biological events in early disease, we performed blood-based whole genome transcriptomic analysis on these participants and 15 active patients with TB. We found transcripts representing the classical complement pathway and Fcγ receptor 1 overabundant from subclinical stages of disease. Levels of circulating immune (antibody/antigen) complexes also increased in subclinical disease and were highly correlated with C1q transcript abundance. To validate our findings, we analyzed transcriptomic data from a publicly available dataset where samples were available in the 2 y before TB disease presentation. Transcripts representing the classical complement pathway and Fcγ receptor 1 were also differentially expressed in the 12 mo before disease presentation. Our results indicate that levels of antibody/antigen complexes increase early in disease, associated with increased gene expression of C1q and Fcγ receptors that bind them. Understanding the role this plays in disease progression may facilitate development of interventions that prevent this, leading to a more favorable outcome and may also be important to diagnostic development.

Entities:  

Keywords:  HIV; complement; immune complex; incipient disease; tuberculosis

Mesh:

Substances:

Year:  2018        PMID: 29339504      PMCID: PMC5798330          DOI: 10.1073/pnas.1711853115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Drug-resistant tuberculosis in patients with minimal symptoms: favourable outcomes in the absence of treatment.

Authors:  M Loveday; A Ramjee; G Osburn; I Master; G Kabera; J C M Brust; N Padayatchi; R Warren; G Theron
Journal:  Int J Tuberc Lung Dis       Date:  2017-05-01       Impact factor: 2.373

Review 2.  The role of complement and its receptor in the elimination of immune complexes.

Authors:  J A Schifferli; Y C Ng; D K Peters
Journal:  N Engl J Med       Date:  1986-08-21       Impact factor: 91.245

3.  Common patterns and disease-related signatures in tuberculosis and sarcoidosis.

Authors:  Jeroen Maertzdorf; January Weiner; Hans-Joachim Mollenkopf; Torsten Bauer; Antje Prasse; Joachim Müller-Quernheim; Stefan H E Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

4.  A Functional Role for Antibodies in Tuberculosis.

Authors:  Lenette L Lu; Amy W Chung; Tracy R Rosebrock; Musie Ghebremichael; Wen Han Yu; Patricia S Grace; Matthew K Schoen; Fikadu Tafesse; Constance Martin; Vivian Leung; Alison E Mahan; Magdalena Sips; Manu P Kumar; Jacquelynne Tedesco; Hannah Robinson; Elizabeth Tkachenko; Monia Draghi; Katherine J Freedberg; Hendrik Streeck; Todd J Suscovich; Douglas A Lauffenburger; Blanca I Restrepo; Cheryl Day; Sarah M Fortune; Galit Alter
Journal:  Cell       Date:  2016-09-22       Impact factor: 41.582

5.  A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus.

Authors:  Damien Chaussabel; Charles Quinn; Jing Shen; Pinakeen Patel; Casey Glaser; Nicole Baldwin; Dorothee Stichweh; Derek Blankenship; Lei Li; Indira Munagala; Lynda Bennett; Florence Allantaz; Asuncion Mejias; Monica Ardura; Ellen Kaizer; Laurence Monnet; Windy Allman; Henry Randall; Diane Johnson; Aimee Lanier; Marilynn Punaro; Knut M Wittkowski; Perrin White; Joseph Fay; Goran Klintmalm; Octavio Ramilo; A Karolina Palucka; Jacques Banchereau; Virginia Pascual
Journal:  Immunity       Date:  2008-07-18       Impact factor: 31.745

Review 6.  The role of B cells and humoral immunity in Mycobacterium tuberculosis infection.

Authors:  Lee Kozakiewicz; Jiayao Phuah; Joanne Flynn; John Chan
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

7.  An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.

Authors:  Matthew P R Berry; Christine M Graham; Finlay W McNab; Zhaohui Xu; Susannah A A Bloch; Tolu Oni; Katalin A Wilkinson; Romain Banchereau; Jason Skinner; Robert J Wilkinson; Charles Quinn; Derek Blankenship; Ranju Dhawan; John J Cush; Asuncion Mejias; Octavio Ramilo; Onn M Kon; Virginia Pascual; Jacques Banchereau; Damien Chaussabel; Anne O'Garra
Journal:  Nature       Date:  2010-08-19       Impact factor: 49.962

8.  Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing.

Authors:  Philana Ling Lin; Christopher B Ford; M Teresa Coleman; Amy J Myers; Richa Gawande; Thomas Ioerger; James Sacchettini; Sarah M Fortune; JoAnne L Flynn
Journal:  Nat Med       Date:  2013-12-15       Impact factor: 53.440

9.  Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers.

Authors:  Chloe I Bloom; Christine M Graham; Matthew P R Berry; Fotini Rozakeas; Paul S Redford; Yuanyuan Wang; Zhaohui Xu; Katalin A Wilkinson; Robert J Wilkinson; Yvonne Kendrick; Gilles Devouassoux; Tristan Ferry; Makoto Miyara; Diane Bouvry; Dominique Valeyre; Valeyre Dominique; Guy Gorochov; Derek Blankenship; Mitra Saadatian; Phillip Vanhems; Huw Beynon; Rama Vancheeswaran; Melissa Wickremasinghe; Damien Chaussabel; Jacques Banchereau; Virginia Pascual; Ling-Pei Ho; Marc Lipman; Anne O'Garra
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

Review 10.  The ongoing challenge of latent tuberculosis.

Authors:  H Esmail; C E Barry; D B Young; R J Wilkinson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237

View more
  31 in total

1.  Tryptophan catabolism reflects disease activity in human tuberculosis.

Authors:  Jeffrey M Collins; Amnah Siddiqa; Dean P Jones; Ken Liu; Russell R Kempker; Azhar Nizam; N Sarita Shah; Nazir Ismail; Samuel G Ouma; Nestani Tukvadze; Shuzhao Li; Cheryl L Day; Jyothi Rengarajan; James Cm Brust; Neel R Gandhi; Joel D Ernst; Henry M Blumberg; Thomas R Ziegler
Journal:  JCI Insight       Date:  2020-05-21

2.  Increasing reproducibility, robustness, and generalizability of biomarker selection from meta-analysis using Bayesian methodology.

Authors:  Laurynas Kalesinskas; Sanjana Gupta; Purvesh Khatri
Journal:  PLoS Comput Biol       Date:  2022-06-27       Impact factor: 4.779

3.  Development and Validation of a Parsimonious Tuberculosis Gene Signature Using the digital NanoString nCounter Platform.

Authors:  Vaishnavi Kaipilyawar; Yue Zhao; Xutao Wang; Noyal M Joseph; Selby Knudsen; Senbagavalli Prakash Babu; Muthuraj Muthaiah; Natasha S Hochberg; Sonali Sarkar; Charles R Horsburgh; Jerrold J Ellner; W Evan Johnson; Padmini Salgame
Journal:  Clin Infect Dis       Date:  2022-09-29       Impact factor: 20.999

4.  Transfer transcriptomic signatures for infectious diseases.

Authors:  Julia di Iulio; Istvan Bartha; Roberto Spreafico; Herbert W Virgin; Amalio Telenti
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-01       Impact factor: 11.205

5.  Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection.

Authors:  Catherine Riou; Elsa du Bruyn; Cari Stek; Remy Daroowala; Rene T Goliath; Fatima Abrahams; Qonita Said-Hartley; Brian W Allwood; Nei-Yuan Hsiao; Katalin A Wilkinson; Cecilia S Lindestam Arlehamn; Alessandro Sette; Sean Wasserman; Robert J Wilkinson
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 14.808

6.  Micro-Computed Tomography Analysis of the Human Tuberculous Lung Reveals Remarkable Heterogeneity in Three-dimensional Granuloma Morphology.

Authors:  Gordon Wells; Joel N Glasgow; Kievershen Nargan; Kapongo Lumamba; Rajhmun Madansein; Kameel Maharaj; Robert L Hunter; Threnesan Naidoo; Llelani Coetzer; Stephan le Roux; Anton du Plessis; Adrie J C Steyn
Journal:  Am J Respir Crit Care Med       Date:  2021-09-01       Impact factor: 30.528

7.  Host transcriptomic signatures of tuberculosis can predict immune reconstitution inflammatory syndrome in HIV patients.

Authors:  Stanley Kimbung Mbandi; Hannah Painter; Adam Penn-Nicholson; Asma Toefy; Mzwandile Erasmus; Willem A Hanekom; Thomas J Scriba; Rachel P J Lai; Suzaan Marais; Helen A Fletcher; Graeme Meintjes; Robert J Wilkinson; Mark F Cotton; Savita Pahwa; Mark J Cameron; Elisa Nemes
Journal:  Eur J Immunol       Date:  2022-04-27       Impact factor: 6.688

Review 8.  Type I interferons in tuberculosis: Foe and occasionally friend.

Authors:  Lúcia Moreira-Teixeira; Katrin Mayer-Barber; Alan Sher; Anne O'Garra
Journal:  J Exp Med       Date:  2018-04-17       Impact factor: 17.579

Review 9.  The value of transcriptomics in advancing knowledge of the immune response and diagnosis in tuberculosis.

Authors:  Akul Singhania; Robert J Wilkinson; Marc Rodrigue; Pranabashis Haldar; Anne O'Garra
Journal:  Nat Immunol       Date:  2018-10-17       Impact factor: 25.606

Review 10.  Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?

Authors:  Hyun-Eui Park; Wonsik Lee; Min-Kyoung Shin; Sung Jae Shin
Journal:  Front Immunol       Date:  2021-06-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.